Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 196 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: GLP-1 receptor agonist Clear all

Conditions: Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 40 Years to 79 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Grade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia, Metabolic Comorbidities
Interventions: Tirzepatide; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Obesity and Overweight
Interventions: NA-931, Tirzepatide, NA-931 150 mg + no Tirzepatide; Drug
Lead sponsor: Biomed Industries, Inc.; Industry
Eligibility: 19 Years to 80 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 5 more

Conditions: Type 2 Diabetes, Liver Disease
Interventions: Behavioral Treatment; Device
Lead sponsor: SIPPA Solutions INC; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Jamaica, New York

Conditions: Aging, LONGEVITY 1
Interventions: Zepbound; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 55 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Prediabetes / Type 2 Diabetes
Interventions: Metformin, GLP-1A, MED; Drug · Dietary Supplement
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hypothalamic Obesity
Interventions: Exenatide, placebo; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 10 Years to 25 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Nashville, Tennessee • Seattle, Washington

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 74
States / cities: Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more

Conditions: Healthy, Hepatic Insufficiency
Interventions: LY3502970; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Diabetes Mellitus, Type 2 Diabetes
Interventions: Diabetes Staging System (DSS) use among Primary Care Teams; Other
Lead sponsor: Durham VA Medical Center; Federal
Eligibility: 25 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Obesity & Overweight
Interventions: Remote Monitoring Program; Other
Lead sponsor: Stanford University; Other
Eligibility: 10 Years to 18 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Obesity, Overweight
Interventions: Orforglipron, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 27
States / cities: Birmingham, Alabama • Pelham, Alabama • Santa Ana, California + 21 more

Conditions: Pancreatic Cancer, Colorectal Cancer, Hepatocellular Carcinoma
Interventions: GLP1-RA (semaglutide); Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Interventions: Metformin, Sulfonylurea, DPP-4 inhibitor, SGLT2 inhibitor, GLP1 receptor agonist; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 4,888 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Nashville, Tennessee

Conditions: Type 2 Diabetes
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Fresno, California • New Port Richey, Florida • Nashua, New Hampshire + 2 more

Conditions: Obesity
Interventions: Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion, Liraglutide; Drug
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 35 Years to 60 Years
Enrollment: 30 participants
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: New Orleans, Louisiana

Conditions: Diabetes Mellitus, Type 2
Interventions: Lixisenatide (AVE0010), Placebo, Basal Insulin, Metformin, Pen auto-injector; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Exenatide, Dapagliflozin, Exenatide and Dapagliflozin; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide; Drug
Lead sponsor: Emory University; Other
Eligibility: 65 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Alcohol Use Disorder
Interventions: Exenatide, Sham injection; Drug · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 21 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: GI Symptoms
Interventions: Prebiotic Soda; Other
Lead sponsor: Olipop, PBC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Kidney Diseases
Interventions: dulaglutide injection; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Polycystic Ovary Syndrome, Obesity
Interventions: Exenatide once weekly (EQW ), Dapagliflozin (DAPA), EQW plus DAPA, Dapagliflozin plus Glucophage (MET ER), Phentermine /Topiramate (PHEN/ TPM) ER; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
Interventions: Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment; Procedure · Drug
Lead sponsor: Ali Aminian; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM

Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

Digital Behavioral Therapy to Reduce Diabetes and Liver Disease Risk

Tirzepatide to Slow Biological Aging

Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention

Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

A Study of LY3502970 in Participants With Impaired and Normal Liver Function

The Diabetes Staging System in Patient Aligned Care Teams

Stanford Pediatric Healthy Weight Index

A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease

A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

Anti-obesity Pharmacotherapy and Inflammation

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin

Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes

The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers

A Pilot Study Evaluating the Impact of a Prebiotic Soda on Gastrointestinal Symptoms in Users of GLP-1 Agonists

Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease

EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

Metabolic Surgery for Atrial Fibrillation Elimination